triple hormone receptor agonist retatrutide for obesity in Johnson County Retatrutide—A Game Changer in Obesity

Cagrilintide vs tirzepatide Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces weight loss of 15% to 22% depending on the dose and population

Some newer lactation resources discuss very low or undetectable transfer of certain injectable GLP-1 medications into breast milk in small studies

Additional info National Institute of Diabetes and Digestive and Kidney Disorders National Kidney Foundation About the Reviewer Howard E

174 WangX.-L.WolffS

#Diabetes #Obesity #GLP1 #HealthcareInnovation #Pharmaceuticals #CardiometabolicHealth To view or add a comment, sign in More Relevant Posts Eli Lilly and Company reported results from ACHIEVE-3, the first head-to-head #Phase3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with #Type2Diabetes

The rules on peptides are in flux, and they might soon change to the point that DSIP, and other peptides on the restricted list, becomes more readily available